IL195431A0 - Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia - Google Patents

Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia

Info

Publication number
IL195431A0
IL195431A0 IL195431A IL19543108A IL195431A0 IL 195431 A0 IL195431 A0 IL 195431A0 IL 195431 A IL195431 A IL 195431A IL 19543108 A IL19543108 A IL 19543108A IL 195431 A0 IL195431 A0 IL 195431A0
Authority
IL
Israel
Prior art keywords
schizophrenia
alzheimer
pain
disease
effective
Prior art date
Application number
IL195431A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Tomaszewski Miroslaw
Cheng Yun Xing
Pourashraf Mehrnaz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Tomaszewski Miroslaw, Cheng Yun Xing, Pourashraf Mehrnaz filed Critical Astrazeneca Ab
Publication of IL195431A0 publication Critical patent/IL195431A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IL195431A 2006-06-09 2008-11-20 Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia IL195431A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81220906P 2006-06-09 2006-06-09
PCT/SE2007/000554 WO2007142583A1 (en) 2006-06-09 2007-06-08 Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia.

Publications (1)

Publication Number Publication Date
IL195431A0 true IL195431A0 (en) 2009-08-03

Family

ID=38801727

Family Applications (1)

Application Number Title Priority Date Filing Date
IL195431A IL195431A0 (en) 2006-06-09 2008-11-20 Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia

Country Status (18)

Country Link
US (1) US7956069B2 (https=)
EP (1) EP2035411A1 (https=)
JP (1) JP2009539831A (https=)
KR (1) KR20090018210A (https=)
CN (1) CN101501025A (https=)
AR (1) AR061305A1 (https=)
AU (1) AU2007256012A1 (https=)
BR (1) BRPI0712331A2 (https=)
CA (1) CA2654138A1 (https=)
EC (1) ECSP088966A (https=)
IL (1) IL195431A0 (https=)
MX (1) MX2008015136A (https=)
NO (1) NO20085270L (https=)
RU (1) RU2008147542A (https=)
SA (1) SA07280303B1 (https=)
TW (1) TW200813018A (https=)
UY (1) UY30397A1 (https=)
WO (1) WO2007142583A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815405A (en) * 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
UY31672A1 (es) * 2008-02-28 2009-09-30 "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"
US20090221642A1 (en) * 2008-03-03 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176
US20090275574A1 (en) * 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300
GB0817982D0 (en) * 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
EP2398320A4 (en) * 2009-02-19 2012-09-19 Univ Vanderbilt ALLOSTERIC ANTAGONISTS OF AMIDOBIPIPERIDINECARBOXYLATE M1, ANALOGUES AND DERIVATIVES THEREOF, AND METHODS FOR THEIR MANUFACTURE AND USE
US20100286124A1 (en) * 2009-04-10 2010-11-11 Auspex Pharmaceuticals, Inc. Prop-2-yn-1-amine inhibitors of monoamine oxidase type b
RU2013114771A (ru) * 2010-09-03 2014-10-10 Янссен Фармацевтика Нв Диамиды азетидинила как ингибиторы моноацилглицерол липазы
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
EP3774746A1 (en) * 2018-04-06 2021-02-17 Aquinox Pharmaceuticals (Canada) Inc. Indene derivatives useful in treating pain and inflammation

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3066434D1 (en) 1979-11-21 1984-03-08 Kyowa Hakko Kogyo Kk Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
ATE216580T1 (de) 1993-07-16 2002-05-15 Merck & Co Inc Benzoxazinon- und benzopyrimidinon- piperidinyl- verbindungen als tokolytische oxytocin-rezeptor- antagonisten
JP2002515008A (ja) * 1994-10-27 2002-05-21 メルク エンド カンパニー インコーポレーテッド ムスカリン・アンタゴニスト
US5756508A (en) * 1995-10-31 1998-05-26 Merck & Co., Inc. Muscarine antagonists
WO1997016192A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
US5756497A (en) 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
DE59711622D1 (de) 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
AU2307999A (en) * 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
JP2000323278A (ja) 1999-05-14 2000-11-24 Toray Ind Inc 発光素子
ATE275141T1 (de) 1999-10-13 2004-09-15 Banyu Pharma Co Ltd Substituierte imidazolin-derivate
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
EP1309593B1 (en) 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
JP2002302675A (ja) 2001-04-06 2002-10-18 Fuji Photo Film Co Ltd 液晶組成物、それを用いた液晶素子およびアゾ化合物
US6872733B2 (en) * 2001-04-18 2005-03-29 Euro-Celtique S.A. Benzimidazolone compounds
NZ551453A (en) 2001-04-18 2008-02-29 Euro Celtique Sa Nociceptin analogs for the treatment of pain
JPWO2002085890A1 (ja) * 2001-04-20 2004-08-12 萬有製薬株式会社 ベンズイミダゾロン誘導体
ATE516030T1 (de) * 2001-10-02 2011-07-15 Acadia Pharm Inc Benzimidazolidinon-derivate als muscarinische mittel
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
PT1499316E (pt) 2002-04-18 2008-06-30 Schering Corp Derivados de (1-4-piperidinil)benzimidazole úteis como antagonistas de histamina h3
JP2005532361A (ja) * 2002-06-17 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症の治療用の眼科用組成物
WO2004069828A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation ピペリジン化合物およびその医薬用途
CA2524221A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted heteroaryls as inhibitors of protein tyrosine phosphatases
US20050250794A1 (en) 2003-12-19 2005-11-10 Andrew Napper Methods of treating a disorder
US20050228023A1 (en) 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
AU2005249494A1 (en) * 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP1790637B1 (en) 2004-09-13 2014-01-29 Ono Pharmaceutical Co., Ltd. Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient
CA2581930A1 (en) 2004-09-27 2006-04-06 Jane Trepel Modulating mxa expression
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
WO2006130469A1 (en) 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules
TW200815351A (en) 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
TW200815405A (en) 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
UY31672A1 (es) 2008-02-28 2009-09-30 "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"
US20090221642A1 (en) 2008-03-03 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176
US20090275574A1 (en) 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300

Also Published As

Publication number Publication date
JP2009539831A (ja) 2009-11-19
SA07280303B1 (ar) 2011-02-23
KR20090018210A (ko) 2009-02-19
AU2007256012A1 (en) 2007-12-13
WO2007142583A1 (en) 2007-12-13
CN101501025A (zh) 2009-08-05
TW200813018A (en) 2008-03-16
NO20085270L (no) 2009-01-07
ECSP088966A (es) 2009-01-30
CA2654138A1 (en) 2007-12-13
US20070287695A1 (en) 2007-12-13
UY30397A1 (es) 2008-01-31
EP2035411A1 (en) 2009-03-18
MX2008015136A (es) 2008-12-10
RU2008147542A (ru) 2010-07-20
BRPI0712331A2 (pt) 2012-04-03
US7956069B2 (en) 2011-06-07
AR061305A1 (es) 2008-08-20

Similar Documents

Publication Publication Date Title
EP2035412A4 (en) MUSCARINIC RECEPTOR AGONISTS FOR THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA
ZA200808825B (en) Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's disease and/or schizophrenia
IL195431A0 (en) Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia
IL264736B (en) Pharmaceutical preparations containing zonisamide for use in the treatment of diseases related to Alzheimer's disease
EP2091566A4 (en) COMBINATION THERAPIES AGAINST ALZHEIMER DISEASE AND SIMILAR ILLNESSES
EP2152318A4 (en) COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
PL2104682T3 (pl) Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
ZA201007460B (en) Use of epothelone in treating tau-associated disease including alzheimer's disease
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
IL185300A0 (en) New pharmaceutical compositions useful in the treatment of parkinson's disease
IL195441A0 (en) Use of trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine and its formamide in the preparation of medicaments for the treatment of pain disorders
EP2010215A4 (en) METHOD AND COMPOSITIONS FOR TREATING MORBUS CROHN
EP2285798A4 (en) AGONISTS OF MUSCARINIC RECEPTORS USEFUL IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA
EP2214488A4 (en) COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE AND RELATED DISORDERS
IL211957A0 (en) Composition for the use in the treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers
EP1954800A4 (en) COMPOSITION AND USE OF PHYTO-PERCOLATE FOR THE TREATMENT OF DISEASE
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
EP1928247A4 (en) COMPOSITION AND USE OF PHYTO-PERCOLATE FOR THE TREATMENT OF DISEASE
HK1128117A (en) Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia
EP2127658A4 (en) THERAPEUTIC AGENT AGAINST MORBUS MENIERE
EP2174666A4 (en) MEDICAL AGENT FOR THE PREVENTION OR TREATMENT OF ALZHEIMER DISEASE
HK1128118A (en) Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia.
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
HK1127773A (en) Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's disease and/or schizophrenia